Abstract
Most patients who should be on lipid-lowering therapy are not receiving it, and most patients who are receiving it are not reaching their appropriate low-density lipoprotein (LDL) goals. This is in part because physicians and patients fear side effects of statins and other lipid-lowering agents. Ezetimibe (Zetia), a new lipid-lowering drug, may help physicians close this "treatment gap" in more patients, especially in combination with a statin.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 777-783 |
| Number of pages | 7 |
| Journal | Cleveland Clinic journal of medicine |
| Volume | 70 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1 2003 |
ASJC Scopus subject areas
- General Medicine
Divisions
- Hospital Medicine
Fingerprint
Dive into the research topics of 'Lipid-lowering: Can ezetimibe help close the treatment gap?'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS